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Previewsprovide evidence that profiling of vari-
ability in chromatin state is rapidly extend-
ing its reach both broadly across individ-
uals and deeply into smaller amounts of
primary tissues (Table 1). While measure-
ment of sequence variation at both the
individual and population levels is a
necessary prerequisite for unraveling ge-
netic contributions to diseases and traits,
all genetic variation is ultimately inter-
preted in a cellular epigenetic context.
The expanded application of chromatin
profiling across cell-type, genetic, and
cellular axes will surely offer novel insight
into the precise molecular characteriza-
tion of cellular diversity and its relation-
ship to human traits and diseases.
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Genetic tools to engineer a prominent member of the human gut microbiome represent initial steps toward
cell-based diagnostics and therapeutics.Obesity, diabetes, colon cancer, and in-
flammatory bowel disease have all been
correlated with changes in the composi-
tion of the human gut microbiome (Cho
and Blaser, 2012), but understanding,
diagnosing, and therapeutically treating
gut dysbioses will require more sophisti-
cated tools than what we currently
possess. In this issue, Mimee et al.
(Mimee et al., 2015) develop a syntheticbiology toolbox for engineering a non-
model, prominent member of the human
gut microbiome, Bacteroides thetaiotao-
micron, to accurately detect and pre-
cisely respond to gut-localized signals.
This work provides a platform for engi-
neering this important bacterium to
perform useful tasks, and an example
of how synthetic biology tools devel-
oped in model organisms can be adapt-ed for non-model, biologically relevant
organisms.
Scientists studying the human micro-
biome have lately shifted their focus from
describing its correlations with disease to
understanding the underlying causes of
these correlations at the molecular level.
Elegant studies using microbiome trans-
plantation in mice provide strong support
for the hypothesis that changes in thems 1, July 29, 2015 ª2015 Elsevier Inc. 21
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Figure 1. Engineering Bacteroides sp. to Eradicate a Pathogen through the Production of a
Small Molecule Antibiotic
(A–C) In this hypothetical application of the toolbox described by Mimee et al., a biosynthetic gene cluster
(red, white, brown, and yellow genes) for the synthesis and secretion of a small molecule antibiotic is
engineered in a Bacteroides strain. (A) Signal transduction. The initial expression of the gene cluster is trig-
gered after sensing a carbohydrate signal administered through diet or a pathogen-derived small mole-
cule. Different combinations of promoters and ribosome binding sites control the expression of different
genes in the gene cluster, to produce the antibiotic compound at a desired level. (B) Signal propagation. A
circuit that activates after a specified amount of time, or a circuit that responds to high intracellular levels of
the produced molecule, controls the expression of the export machinery (black gene). Once secreted, the
small molecule antibiotic eliminates the pathogen. (C) Signal termination. Finally, a CRISPR interference
circuit (green gene and green RNA) stops the expression of the gene cluster in response to a second
diet-based carbohydrate signal, or to the absence of the pathogen-derived small molecule. The initiation
of each of the steps in this example can be recorded using a genetic memory array (not shown).
Cell Systems
Previewsmicrobiome play an active role in disease
rather than simply being a consequence
of it. For example, transfer of the micro-
biome alone from mice genetically
induced to have ulcerative colitis to non-
genetically predisposed recipients is suffi-
cient to induce inflammation (Garrett et al.,
2007). The growing evidence for a role
of the microbiome in disease not only
inspires detailed mechanistic studies to
identify the specific microbes, genes, and
molecules involved, but also highlights
the potential value of manipulating the mi-
crobiome to diagnose and treat diseases.
Efforts to manipulate the composition
and function of the microbiome have
been ongoing for decades. These include
the introduction of new members to the
community through the use of probiotics
and fecal transplantation, for example,
and the removal of unwanted members
by methods such as antibiotics and intes-
tinal lavage. However, these manipula-
tion strategies are nonspecific, and often
result in unpredictable outcomes.
More recently, targeted strategies have
been employed where one bacterium
is engineered to perform a very specific
function in the gastrointestinal tract.
These functions range from secreting a
therapeutic molecule (mostly peptides
and small proteins) to detecting a partic-
ular signal, such as small molecules
derived from other bacteria, food, or22 Cell Systems 1, July 29, 2015 ª2015 Elsevcancerous or inflamed tissues (Claesen
and Fischbach, 2015).
Notably, almost all of these strategies
have been used in model organisms
that either transiently colonize the gastro-
intestinal tract (Lactococcus lactis), or are
naturally present asminor members of the
healthy microbiome (Escherichia coli).
The drawback of using such organisms
is the need to constantly administer the
engineered bacterium if a long-term effect
is sought and to introduce it in a relatively
high titer. Although engineering common
members of the microbiome is an attrac-
tive solution to these problems, the lack
of genetic tools for these non-model
organisms has hampered their develop-
ment as alternative chassis for manipu-
lating the microbiome.
A successful microbial diagnostic or
therapeutic agent must to able to detect
a particular signal with high fidelity,
integrate this signal through precise intra-
cellular circuitry, and respond to this
signal at the appropriate level. Mimee
et al. describe genetic tools that allow
B. thetaiotaomicron to efficiently perform
all three of these functions.
For signal detection, Mimee et al.
exploit three transcriptional circuits natu-
rally used by Bacteroides for detecting
and responding to different carbohy-
drates and further determine the fold
change in gene expression achievedier Inc.upon their usage. The authors also engi-
neer a LacO (operator)/LacI (repressor)
pair, previously adapted from E. coli for
use in Bacteroides, to obtain two IPTG-
inducible promoters with different induc-
tion profiles. Importantly, Mimee et al.
show that these four systems are orthog-
onal and that they can be induced in
response to four different carbohydrates
(rhamnose, chondroitin sulfate, arabinol-
galactan, and IPTG) with no crosstalk
between them. These inducible systems
can elicit a transcriptional response that
spans a range of 8- to 104-fold change
in gene expression.
As an example of signal integration and
propagation, Mimee et al. use CRISPR
interference, in which an RNA-guided,
catalytically inactive Cas9 protein binds
to DNA and blocks transcription, to spe-
cifically knockdown the expression of
certain genes in response to IPTG induc-
tion. In addition, they implement a carbo-
hydrate-inducible memory switch using a
DNA memory array that was previously
constructed in E. coli. Briefly, this memory
switch makes use of a series of serine
integrases that catalyze DNA inversion
events at cognate recognition sequences
in a specific and unidirectional fashion.
When inducible, these binary switches
can efficiently record the exposure of
the cell harboring the memory array to
different cues in the gastrointestinal tract,
allowing scientists to learn the molecular
details of a bacterium’s life.
Finally, for fine control over response
to stimuli, the authors constructed and
characterized a library of constitutive pro-
moters and ribosome binding sites that
spans 104-fold expression levels. Notably,
they show that circuits integrating signal
detection, genetic memory, and CRISPR
interefence function as expected when
engineered B. thetaiotaomicron is intro-
duced into the gut microbiome of mice.
The applications of this set of tools are
enormous and break ground for a new
era of engineered chassis organisms
that can be used to build microbiome-
based diagnostics and therapeutics. In
the future, one can imagine the use of
different pairs of promoters and ribosome
binding sites to tightly regulate the expres-
sion of different genes in a biosynthetic
gene cluster for a small molecule thera-
peutic (e.g., an antibiotic), engineered in
a microbiome-derived Bacteroides strain
(Figure 1). The in vivo expression of this
Cell Systems
Previewsgene cluster could be controlled by the
level of a carbohydrate administered in
the diet, or preferably, by a specific small
molecule produced by the target path-
ogen itself. Decoupling of the synthesis
and secretion of the small molecule (e.g.,
to reach an effective local therapeutic
dose) can be achieved by putting the
export machinery under the control of an
inducible circuit that responds only to
high intracellular levels of the small mole-
cule, or by engineering a time delay
between the synthesis and secretion of
the molecule. Once the therapeutic effect
has been achieved (e.g., the elimination
of a pathogen), CRISPR interference can
be used to knock down residual expres-
sion of the therapeutic genes or to elimi-
nate the chassis itself by targeting an
essential gene. This final step could be
triggered by a second signal administered
in diet, or by the absence of the pathogen-
derived small molecule. This entire series
of events could be recorded on memory
switches and read through analysis of
the Bacteroides genome in host feces,
providing timely snapshots of what is
happening in vivo.
Although it is still early days for its
approval, using engineered commensals
to produce therapeutic molecules (as in
the aforementioned scenario) may be
preferred over using oral or systemic
drugs for several reasons. First, commen-
sals naturally occupy specific niches in
the gastrointestinal tract, allowing drug
delivery to a very defined site. Subse-
quently, the dosage needed to obtain a
local therapeutic effect would be much
lower than needed if orally administered,
and many adverse effects could in turn
be eliminated. Second, because the pro-
duction of a therapeutic molecule can be
precisely controlled in engineered bacte-
ria, long-term control of diseases can be
achieved using a single organism that
produces the drug only when needed.
This is reminiscent to the currently sought
after ‘‘artificial pancreas’’ for managing
type 1 diabetes, in which a continuous
glucose monitoring system is paired with
an insulin pump and a small computer
that determines and triggers the delivery
of the needed insulin dose based on thecurrent glucose level. Last, using an engi-
neered bacterium to produce and deliver
one or more therapeutic molecules could
provide an economical alternative to the
costly production, formulation, distribu-
tion, and storage of drugs. This is even
more applicable in the cases where a
drug is specially formulated or adminis-
tered via intramuscular or subcutaneous
injection to avoid degradation in the
stomach.
Beyond diagnostics and therapeutics,
there are clear advantages of using a
cell-based delivery system for basic
research. For example, there are no
good models available for studying the
precise effects of the in situ production
of pathogen- or commensal-derived anti-
biotics on the composition of the micro-
biome. A microbial chassis that encodes
an engineered biosynthetic gene cluster
for the production of a small molecule
antibiotic, and several circuits for sensing
and recording its local environment, will
enable scientists tomeasure these effects
in a timely and localized manner.
More genetic tools will be needed in the
future. For example, genetic circuits need
to be engineered to detect non-carbohy-
drate signals. Systems that respond to
pathogen-derived smallmolecules (Saeidi
et al., 2011) and the inflammatory marker
nitric oxide (Archer et al., 2012), were
developed previously in E. coli and
can possibly be adapted for use in
Bacteroides. Additionally, self-elimination
systems, working through lysis (Kong
et al., 2008) or auxotrophy (Steidler et al.,
2003), will also be important to satisfy
safety concerns.
Genetic tools for other prominent gut
bacteria also need to be developed.
Notably, the two bacterial phyla that
dominate the gut microbiome of healthy
humans are the Bacteroidetes (the
phylum in which Bacteroides sp. reside),
and the Firmicutes. These two phyla
occupy distinct niches of the human in-
testine, and perform different activities
(Mahowald et al., 2009). Unlike the Bac-
teroidetes, most prominent Firmicutes,
such as Closridium sp. and Ruminococ-
cus sp., are not easily amenable to ge-
netic manipulations and are not well stud-Cell Systeied with respect to regulation and signal
transduction. Like B. thetaiotaomicron
for the Bacteroidetes, developing a
genetic toolbox for a member of the gut--
derived Firmicutes is essential to gain ac-
cess to the unique niches occupied by
members of this phylum.
Finally, other than a vaginal strain of
Lactobacillus jensenii engineered to pro-
duce the HIV-1 entry inhibitor protein
cyanovirin-N (Lagenaur et al., 2011), most
microbiome engineering attempts have
focused on the gut microbiome. Ideally,
one would want to develop tools for
several bacterial chassis for each micro-
biome-rich body site (skin, gastrointestinal
tract, urogenital tract, mouth, and respira-
tory tract). Engineeringmicrobiome-based
diagnostics and therapeutics supports
the natural progression of microbiome
research questions from ‘‘which bacteria
are there?’’ to ‘‘what are they doing?’’ to
‘‘how can we manipulate them?’’
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